1. Results of all outcomes analysed (all phlebotonics).
| Variables | Dichotomous | Continuous |
| Oedema | RR 0.70 (0.63 to 0.78) | ‐ |
| Oedema (mm) | ‐ | MD ‐4.27 (‐5.61 to ‐2.93) |
| Oedema (volume) | ‐ | SMD ‐0.24 (‐0.33 to ‐0.15) |
| Ulcer cured | NS | ‐ |
| Trophic disorders | RR 0.87 (0.81 to 0.95) | ‐ |
| Pain | ‐ | SMD ‐0.35 (‐0.54, ‐0.17) |
| Cramps | RR 0.72 (0.58 to 0.89) | ‐ |
| Restless legs | RR 0.81 (0.72 to 0.91) | ‐ |
| Itching | ‐ | ‐ |
| Heaviness | ‐ | ‐ |
| Swelling | RR 0.63 (0.50 to 0.80) | ‐ |
| Paraesthesia | RR 0.67 (0.50 to 0.88) | NS |
| Quality of life | ‐ | NS |
| Global assessment by the participant | ‐ | ‐ |
| Adverse events | RR 1.14 (1.02 to 1.27) | ‐ |
| Note: No measures of effect are specified when I2 was > 75% for the subgroup | ||
RR: risk ratio MD: mean difference NS: non‐significant RR: risk ratio SMD: standardized mean difference